List of Drugs That Could See Massive Price Cuts Under Trump Deal
Summary
President Donald Trump announced that the drug company Regeneron agreed to lower prices on some medications, including cutting the price of the cholesterol drug Praluent from $537 to $225 for patients buying on the TrumpRx website. Regeneron's new and future drugs will have prices matched to those in other countries, as part of the administration’s effort to reduce the high cost of medicine in the U.S.Key Facts
- Regeneron agreed to a deal to lower drug prices, including Praluent, a cholesterol medication.
- Praluent’s price will drop from $537 to $225 on the TrumpRx website.
- New Regeneron medicines will have Most Favored Nation (MFN) prices, matching drug costs in other countries.
- President Trump sent letters last July to 17 major drug companies asking for lower prices; 16 companies already made deals before Regeneron’s agreement.
- Americans pay almost three times more for prescription drugs than people in other wealthy countries.
- There are many Regeneron drugs in development, including treatments for Alzheimer's, various cancers, Parkinson’s disease, and rare blood and liver disorders.
- Some drugs are in early clinical trials (Phase 1 and Phase 2), testing safety and effectiveness before potential approval.
- The price cuts are aimed at making medicines more affordable for Americans as part of the Trump administration’s healthcare goals.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.